BODY COMPOSITION AND ITS ROLE IN DEVELOPMENT OF METABOLIC DISORDERS AND CARDIOVASCULAR DISEASES
https://doi.org/10.15829/1728-8800-2017-5-81-85
Abstract
There are many methods of the body composition assessment, but the most relevant are computed tomography and magnete-resonance tomography. Composition of the body shows the rate of fat amount and distribution in metabolic syndrome (MS) patients. It is known that MS increases the risk of atherosclerosis, arterial hypertension, type 2 diabetes, with further significant increase of cardiovascular morbidity and mortality. MS is associated with subclinical damage of internal organs; and the role of abdominal obesity is high. However, till recently there is no unified understanding of the role of visceral and subcutaneous fat.
About the Authors
O. M. Drapkina
National Research Center for Preventive Medicine of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
L. V. Kupreyshvili
I.M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
V. V. Fomin
I.M. Sechenov First Moscow State Medical University of the Ministry of Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Churchill Livingstone’s Dictionary of Sport and Exercise Science and Medicine. Churchill Livingstone 2008; (1).
2. Cornier M, Després JP, Davis N, et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation 2011; 124 (18): 1996-2019.
3. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373 (9669): 1083-96.
4. Koning L, Merchant AT, Pogue J, et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007; 28 (7): 850-6.
5. Dehghan M, Merchant AT. Is bioelectrical impedance accurate for use in large epidemiological studies? Nutr J 2008; 7 (26).
6. Meng K, Lee CH, Saremi F. Metabolic syndrome and ectopic fat deposition: what can CT and MR provide? Acad Radiol 2010; 17 (10): 1302-12.
7. Lee SY, Gallagher D. Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care 2008; 11 (5): 566-72.
8. Bershtejn LM, Kovalenko IG. “Metabolic healthy” persons with obesity and metabolic symptoms of obesity at persons with normal body weight: what stands behind it? Endocrinology problems 2009; 3: 47-51. Russian (Берштейн Л.М., Коваленко И.Г. “Метаболически здоровые” лица с ожирением и метаболические признаки ожирения у лиц с нормальной массой тела: что за этим стоит? Проблемы эндокринологии 2009; 3: 47-51).
9. Lorenzo A, Martinoli R, Vaia F, et al. Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis 2006; 16 (8): 513-23.
10. Oliveros E, Somers VK, Sochor O, et al. The concept of normal weight obesity. Prog Cardiovasc Dis 2014; 56 (4): 426-33.
11. Drapkina OM, Korneeva ON. Metabolic syndrome and cardiovascular diseases at women: influence of a floor is how big? Serdce 2011; 4: 224-9. Russian (Драпкина О.М.; Корнеева О.Н. Метаболический синдром и сердечно-сосудистые заболевания у женщин: насколько велико влияние пола? Сердце 2011; 4: 224-9).
12. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006; 83 (6): 1237-47.
13. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116 (1): 39-48.
14. Pino ADi, Alagona C, Piro S, et al. Separate impact of metabolic syndrome and altered glucose tolerance on early markers of vascular injuries. Atherosclerosis 2012; 223 (2): 458-62.
15. Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 2010; 31 (6): 737-46.
Review
For citations:
Drapkina O.M., Kupreyshvili L.V., Fomin V.V. BODY COMPOSITION AND ITS ROLE IN DEVELOPMENT OF METABOLIC DISORDERS AND CARDIOVASCULAR DISEASES. Cardiovascular Therapy and Prevention. 2017;16(5):81-85. (In Russ.) https://doi.org/10.15829/1728-8800-2017-5-81-85
Views:
2301
Email this article 
